As of 2025-01-16, the EV/EBITDA ratio of Heron Therapeutics Inc (HRTX) is -13.64. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. HRTX's latest enterprise value is 355.08 mil USD. HRTX's TTM EBITDA according to its financial statements is -26.04 mil USD. Dividing these 2 quantities gives us the above HRTX EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 15.0x - 17.8x | 16.2x |
| Forward P/E multiples | 15.1x - 28.2x | 21.2x |
| Fair Price | (3.39) - (3.87) | (4.02) |
| Upside | -323.2% - -354.3% | -364.5% |
| Date | EV/EBITDA |
| 2025-01-10 | -13.81 |
| 2025-01-08 | -14.10 |
| 2025-01-07 | -14.63 |
| 2025-01-06 | -15.21 |
| 2025-01-03 | -14.46 |
| 2025-01-02 | -14.10 |
| 2024-12-31 | -13.70 |
| 2024-12-30 | -13.58 |
| 2024-12-27 | -13.81 |
| 2024-12-26 | -14.10 |
| 2024-12-24 | -13.99 |
| 2024-12-23 | -14.10 |
| 2024-12-20 | -13.99 |
| 2024-12-19 | -13.70 |
| 2024-12-18 | -13.93 |
| 2024-12-17 | -14.40 |
| 2024-12-16 | -14.57 |
| 2024-12-13 | -14.10 |
| 2024-12-12 | -14.10 |
| 2024-12-11 | -14.63 |
| 2024-12-10 | -15.04 |
| 2024-12-09 | -14.98 |
| 2024-12-06 | -14.22 |
| 2024-12-05 | -14.81 |
| 2024-12-04 | -14.34 |
| 2024-12-03 | -11.65 |
| 2024-12-02 | -11.89 |
| 2024-11-29 | -11.71 |
| 2024-11-27 | -11.53 |
| 2024-11-26 | -11.18 |
| 2024-11-25 | -11.42 |
| 2024-11-22 | -11.01 |
| 2024-11-21 | -10.95 |
| 2024-11-20 | -11.30 |
| 2024-11-19 | -11.71 |
| 2024-11-18 | -11.59 |
| 2024-11-15 | -11.71 |
| 2024-11-14 | -12.00 |
| 2024-11-13 | -11.83 |
| 2024-11-12 | -12.24 |
| 2024-11-11 | -15.51 |
| 2024-11-08 | -14.98 |
| 2024-11-07 | -15.10 |
| 2024-11-06 | -15.27 |
| 2024-11-05 | -15.10 |
| 2024-11-04 | -15.16 |
| 2024-11-01 | -15.16 |
| 2024-10-31 | -14.92 |
| 2024-10-30 | -15.27 |
| 2024-10-29 | -15.10 |